Sobi cuts staff and buys Novimmune drug in refocusSobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst Share XSobi cuts staff and buys Novimmune drug in refocushttps://pharmaphorum.com/news/sobi-cuts-staff-novimmune-drug-refocus/
Novo Nordisk builds cardio claim case for oral semaglutideNovo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has Share XNovo Nordisk builds cardio claim case for oral semaglutidehttps://pharmaphorum.com/news/novo-nordisk-builds-cardio-claim-case-for-oral-semaglutide/
Insys throws in the towel and files for bankruptcyInsys has declared bankruptcy, hard on the heels of its agreement last week to a $225 million payment Share XInsys throws in the towel and files for bankruptcyhttps://pharmaphorum.com/news/insys-throws-in-the-towel-and-files-for-bankruptcy/
Merck bolts on another immunology firm with $773m Tilos dealMerck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its Share XMerck bolts on another immunology firm with $773m Tilos dealhttps://pharmaphorum.com/news/merck-bolts-on-another-immunology-firm-with-773m-tilos-deal/
Sanofi, Lilly and Novo make cases for diabetes drugs at ADAThe American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and Share XSanofi, Lilly and Novo make cases for diabetes drugs at ADAhttps://pharmaphorum.com/news/sanofi-lilly-and-novo-diabetes/
Cost of AZ’s new Cambridge HQ ‘has more than doubled’The cost of AstraZeneca’s new R&D hub and corporate headquarters in Cambridge has swelled to £750 million, more Share XCost of AZ’s new Cambridge HQ ‘has more than doubled’https://pharmaphorum.com/news/cost-of-azs-new-cambridge-hq-has-more-than-doubled/
Insys settles opioid kickback charges in US, paying out $225mInsys Therapeutics has agreed to pay a hefty $225 million to settle criminal and civil investigations into unlawful Share XInsys settles opioid kickback charges in US, paying out $225mhttps://pharmaphorum.com/news/insys-settles-opioid-kickback-charges-in-us-paying-out-225m/
Takeda’s Ninlaro fails phase 3 amyloidosis trialTakeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not Share XTakeda’s Ninlaro fails phase 3 amyloidosis trialhttps://pharmaphorum.com/news/takedas-ninlaro-fails-phase-3-amyloidosis-trial/
Bayer buys into Arvinas protein degrader discovery platformBayer is paying $17.5 million upfront to US biotech Arvinas, tapping into a protein-targeting platform to seek new Share XBayer buys into Arvinas protein degrader discovery platformhttps://pharmaphorum.com/news/bayer-buys-into-arvinas-protein-degrader-discovery-platform/
The importance of virtual trials for patient engagementHow virtual trials help diminish barriers to participation and make clinical research easier for patients. When we talk Share XThe importance of virtual trials for patient engagementhttps://pharmaphorum.com/views-and-analysis/the-importance-of-virtual-trials-for-patient-engagement/
Sanofi names ex-Roche cancer guru Dietmar Berger as development leadRoche alumnus Dietmar Berger has joined Sanofi as head of development following a short stint in biotech. In Share XSanofi names ex-Roche cancer guru Dietmar Berger as development leadhttps://pharmaphorum.com/news/sanofi-names-ex-roche-cancer-guru-dietmar-berger-as-development-lead/
Amicus expands gene therapy collaborationAmicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania have announced a major expansion Share XAmicus expands gene therapy collaborationhttps://pharmaphorum.com/news/amicus-expands-gene-therapy-collaboration/
BioMarin seeks haemophilia gene therapy approval after promising dataBioMarin is set to file for approval for its haemophilia gene therapy valoctocogene roxaparvovec, after it achieved pre-specified Share XBioMarin seeks haemophilia gene therapy approval after promising datahttps://pharmaphorum.com/news/biomarin-seeks-haemophilia-gene-therapy-approval-after-promising-data/
Pfizer’s Lyrica fails phase 3 trial in epilepsyPfizer’s Lyrica has failed to meet its primary endpoint in a phase 3 trial in primary generalised tonic-clonic Share XPfizer’s Lyrica fails phase 3 trial in epilepsyhttps://pharmaphorum.com/news/pfizers-lyrica-fails-phase-3-trial-in-epilepsy/
Teva settles Oklahoma opioid lawsuit ahead of trialTeva has opted to settle the first trial among hundreds of cases that accuse it and other drugmakers Share XTeva settles Oklahoma opioid lawsuit ahead of trialhttps://pharmaphorum.com/news/teva-settles-oklahoma-opioid-lawsuit-ahead-of-trial/
R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo disappointmentsNovartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company Share XR&D Roundup: Novartis pipeline, CRISPR funding and Opdivo disappointmentshttps://pharmaphorum.com/views-and-analysis/rd-roundup-novartis-crispr-opdivo/
EU regulators accept Novartis’ triple asthma comboEuropean regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments Share XEU regulators accept Novartis’ triple asthma combohttps://pharmaphorum.com/news/eu-regulators-accept-novartis-triple-asthma-combo/
Novartis shows off pipeline – including 25 potential blockbustersNovartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company Share XNovartis shows off pipeline – including 25 potential blockbustershttps://pharmaphorum.com/news/novartis-shows-off-pipeline-including-25-potential-blockbusters/
